PMLive7h
FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours
The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...
Managed Healthcare Executive5d
FDA Approves Cabometyx to Treat Advanced Pancreatic Cancer
Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.
BioSpace15h
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...
Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement ...
Zacks.com on MSN4d
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...
PharmiWeb9h
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Junshi Biosciences Announces Toripalimab's Approval in Singapore
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...
Pharmabiz13h
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Tempest Reports Year End 2024 Financial Results and Provides Business Update
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement of ...
PharmiWeb3h
IMFINZI® (durvalumab) approved in the US as first…
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
TriSalus Life Sciences expects 50% sales growth and EBITDA positivity in 2025. See why TLSI stock could benefit, with key ...
Le Lézard7h
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...